Business
Collaboration Agreement with SRI International Inc
Collaboration Agreement with SRI International Inc.
About this update from Thalia Therapeutics Plc
[{"type":"text","content":"\n\n 25 April 2024\nN4 Pharma plc\n (\"N4 Pharma\" or the \"Company\")\n \nCollaboration Agreement with SRI International Inc.\n \nN4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system designed to carry nucleotides to be developed as cancer treatments and vaccines, is delighted to announce that it has entered into a research collaboration agreement (the \"Agreement\") with SRI International, an independent nonprofit research institute based in Silicon Valley, California (\"SRI\") to combine Nuvec® with SRI's proprietary FOX Three Molecular Guidance System™ (\"MGS\") with the aim of co-marketing the resultant combined technology.\n \nUnder the Agreement, the Company will collaborate with SRI to perform research to conjugate its MGS system to Nuvec® in order to increase intracellular delivery to specific target cells. On the back of the combined technology, N4 Pharma and SRI will work collaboratively to develop and pursue new business opportunities.\n \nSRI's MGS technology is designed to overcome cellular barriers that prevent intracellular delivery of large molecule biotherapeutics. The system uses proprietary technology that enables the delivery of macromolecular payloads to the target cell and then on to subcellular locations within those cells. SRI has developed a panel of 50 MGSs targeted at a wide variety of cell types, both diseased and healthy.\n \nSRI has demonstrated that the MGS technology can deliver more than a dozen types of payloads - from functional enzymes, antibodies, and nucleic acids (including siRNA, ASOs, and DNA) to liposomes and nanoparticles - to targeted, intracellular molecular-target locations previously considered unreachable, and therefore, untreatable. For more information on MGS see: https://www.sri.com/platform/fox-three-molecular-guidance-system-mgs/.\n \nThe SRI Biosciences division the Company will be working with integrates basic biomedical research with drug and diagnostics discovery, and preclinical and clinical development. The team has advanced more than 200 drugs to clinical trials, and 25 have reached the market. The division is focused on novel platforms and programs in a variety of therapeutic areas targeting high unmet medical needs.\n \nKathlynn Brown, President of SRI's Bioscience ...